TPWA
SUPN icon

Twin Peaks Wealth Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-171
Closed -$8.84K – 1951
2026
Q1 		$8.84K Buy
+171
New +$8.71K ﹤0.01% 1129
2025
Q3 		– Sell
-144
Closed -$5.94K – 1879
2025
Q2 		$5.94K Buy
+144
New +$4.62K ﹤0.01% 1222

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Twin Peaks Wealth Advisors's SUPN Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 171 shares — an estimated $8.84K sold.

Twin Peaks Wealth Advisors first reported a position in SUPN in Q2 2025 and held it in 2 quarters. The position peaked at $8.84K in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 171 Supernus Pharmaceuticals shares in Q2 2026, an estimated $8.84K.
  • Twin Peaks Wealth Advisors first reported a position in Supernus Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Supernus Pharmaceuticals position peaked at $8.84K in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.